Latest disclosed round
Series D
- Date
- 2025-11-01
- Amount
- USD 115m
- Sector
- Biotech & techbio
- Companies House
- 09931309
Later stage / growth
Artios Pharma
DNA damage response (oncology)
CandidateSeries DCambridge
Evidence status
Review retained
- Identity
- Candidate
- Match
- High candidate
- Operating status
- active
- Data origins
- Core directory, Growth Network, Live Chris T D1
Capital network
0 linked investors
No investor relationship retained.
Funding record
1 disclosed round
| Date | Stage | Amount | Investors |
|---|---|---|---|
| 2025-11-01 | Series D | $115M / €99M | not specified in source for Series D |
Traceability
Source trail
Funding and investor claims retain their public-source links. This is a research snapshot, not a live cap table.